Abstract 657P
Background
T cell engagers (TCE) have been a breakthrough in pts care for multiple malignancies, and the number of phase I clinical trials testing TCE is exponential. The TCE score, based on lactate dehydrogenase (LDH) (LDH > 250 U/l : +1) and C reactive protein (CRP) (CRP > 10g/l : +1) levels, that was developed on a setting cohort (presented at ASCO annual meeting in 2023, Noé Herbel et al., JCO 41, 2573-2573(2023)), was shown to be prognostic for both overall survival (OS) and progression free survival (PFS), as pts with a high score (1-2) had a shorter OS and PFS, with a median PFS of less than two months : thus not presenting a sufficient clinical benefit from the treatment. To confirm the results obtained on the setting cohort, we aimed to prospectively confirm the prognostic ability of the TCE score on a validation cohort.
Methods
Every pts treated with a CD3 TCE in a phase I CT at the drug development department (DITEP) at Gustave Roussy which were not part of the setting cohort, with at least a two months follow up, were included in the validation cohort. Biological and clinical data were prospectively collected to calculate the TCE score, the OS and the PFS. Biological data were collected during the screening period. Estimation of OS and PFS was made using Kaplan-Meir method and comparison using log-rank test. Cox regression model was used in univariate analysis. Predictive power of the TCE score was analyzed using Harrell's C index.
Results
A total of 70 pts treated with CD3 TCE were included in the validation cohort. Median age was 60 years old. The most represented tumor type was ovarian adenocarcinoma (21%). Kaplan-Meier, log-rank test and cox regression model showed that pts with a low score had a longer PFS (HR : 0.42, 95%CI = 0.23 - 0.78, p = 0.005), with a median PFS of 1.8 months (m) for high-risk pts and 5.5 m for low-risk pts. It was also showed that low risk pts have a longer OS (HR : 0.41, 95%CI = 0.18 - 0.93, p = 0.03, with a median 8.7 m for high-risk pts and 12.4 m for low-risk pts. TCE score’s Harrell’s C index for PFS was 0.61 and 0.62 for OS.
Conclusions
The TCE score was developed on a setting cohort to be prognostic for OS and PFS in pts treated with bispecific TCE in phase I CT. We prospectively validated this score on an independent validation cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
744P - A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Presenter: Jung-Min Lee
Session: Poster session 01
745P - Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial
Presenter: Qinglei Gao
Session: Poster session 01
746P - Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
Presenter: Lan Gardner Coffman
Session: Poster session 01
747P - SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)
Presenter: Clare Scott
Session: Poster session 01
748P - Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
Presenter: Ana Oaknin
Session: Poster session 01
750P - Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
Presenter: Claire Friedman
Session: Poster session 01